Check­point Ther­a­peu­tics re­files PD-L1 drug cosi­be­limab af­ter FDA re­jec­tion

Check­point Ther­a­peu­tics is tak­ing a sec­ond shot at ap­proval for its an­ti-PD-L1 can­di­date af­ter the FDA re­ject­ed its first sub­mis­sion around sev­en months ago due …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER